Asset Details
Do you wish to reserve the book?
Rapid‐Onset Therapeutic Effects of Delta Opioid Receptor Agonists on Depression‐Like Behaviors Induced by Chronic Social Defeat Stress
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rapid‐Onset Therapeutic Effects of Delta Opioid Receptor Agonists on Depression‐Like Behaviors Induced by Chronic Social Defeat Stress
Do you wish to request the book?
Rapid‐Onset Therapeutic Effects of Delta Opioid Receptor Agonists on Depression‐Like Behaviors Induced by Chronic Social Defeat Stress
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rapid‐Onset Therapeutic Effects of Delta Opioid Receptor Agonists on Depression‐Like Behaviors Induced by Chronic Social Defeat Stress
2025
Overview
Depression is prevalent, yet conventional antidepressants often require time to produce therapeutic effects. Therefore, novel antidepressants with a more rapid onset of action are urgently needed. This study investigated the potential of δ opioid receptor (DOP) agonists as fast‐acting antidepressants, comparing their efficacy with that of existing treatments. We utilized the chronic social defeat stress (CSDS) model, which closely mimics clinical depressive symptoms, to evaluate the therapeutic effects of DOP agonists (SNC80, KNT‐127) and paroxetine, a selective serotonin reuptake inhibitor. Mice exposed to CSDS for 10 days showed social avoidance toward aggressor mice along with generalized depression and anxiety‐like behaviors. Both DOP agonists demonstrated dose‐dependent therapeutic effects at 1–10 mg/kg and showed improvements within 10–14 days of chronic administration. In contrast, paroxetine alleviated these symptoms after 28 days of treatment. These findings suggest that DOP agonists may offer a faster‐acting alternative to current antidepressant therapies. Delta opioid receptor agonists improved social avoidance, depression, and anxiety‐like symptoms induced by chronic social defeat stress within 14 days of chronic administration. Furthermore, the therapeutic effects were observed earlier than with the existing antidepressant paroxetine (28 days).
Publisher
John Wiley & Sons, Inc,Wiley
Subject
/ Animals
/ Antidepressive Agents - pharmacology
/ anxiety
/ chronic social defeat stress
/ CRISPR
/ Dose-Response Relationship, Drug
/ Females
/ Male
/ Mice
/ opioid delta receptor agonist
/ Original
/ Piperazines - therapeutic use
/ Receptors, Opioid, delta - agonists
/ Stress
/ Stress, Psychological - complications
/ Stress, Psychological - drug therapy
/ Validity
